aquestive
therapeutics
announce
third
quarter
financial
results
recent
business
highlights
november
host
conference
call
november
et
warren
globe
newswire
aquestive
therapeutics
nasdaq
aqst
pharmaceutical
company
focused
developing
commercializing
differentiated
products
address
patients
unmet
needs
solve
therapeutic
problems
announced
today
report
results
third
quarter
ended
september
provide
business
update
market
close
wednesday
november
management
host
conference
call
investors
et
thursday
november
conference
call
accessed
dialing
internationally
followed
conference
id
also
simultaneous
live
webcast
available
investors
section
company
website
https
webcast
archived
days
aquestive
therapeutics
aquestive
therapeutics
pharmaceutical
company
applies
innovative
technology
solve
therapeutic
problems
improve
medicines
patients
aquestive
advancing
proprietary
product
pipeline
treat
cns
conditions
provide
alternatives
invasively
administered
standard
care
therapies
company
also
collaborates
pharmaceutical
companies
bring
new
molecules
market
using
proprietary
technologies
like
proven
capabilities
drug
development
commercialization
statement
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
words
believe
anticipate
plan
expect
estimate
intend
may
negative
terms
similar
expressions
intended
identify
statements
statements
include
limited
statements
regarding
therapeutic
benefits
plans
objectives
regulatory
approvals
ability
cure
deficiencies
identified
fda
complete
response
letter
dated
september
regarding
new
drug
application
libervant
obtain
fda
approval
libervant
market
access
timing
fda
review
approval
libervant
pathways
clinical
trials
plans
approval
libervant
competitors
orphan
drug
approval
resulting
drug
exclusivity
libervant
products
competitors
statements
also
subject
uncertain
impact
global
pandemic
business
including
respect
clinical
trials
including
site
initiation
patient
enrollment
timing
adequacy
clinical
trials
regulatory
submissions
regulatory
reviews
approvals
product
candidates
pharmaceutical
ingredient
raw
materials
supply
chain
manufacture
distribution
sale
demand
products
liquidity
availability
capital
resources
customer
demand
products
services
customers
ability
pay
goods
services
ongoing
availability
appropriate
labor
force
skilled
professionals
given
uncertainties
company
unable
provide
assurance
operations
maintained
planned
prior
pandemic
statements
based
current
expectations
beliefs
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
described
statements
risks
uncertainties
include
limited
risks
associated
ability
obtain
fda
approval
advance
libervant
product
candidates
market
company
development
work
including
delays
changes
timing
cost
success
product
development
activities
clinical
trials
plans
risk
delays
fda
approval
libervant
drug
candidates
failure
receive
approval
risk
ability
demonstrate
fda
clinical
superiority
within
meaning
fda
regulations
drug
candidate
libervant
relative
diazepam
rectal
gel
nasal
spray
products
including
establishing
major
contribution
patient
care
within
meaning
fda
regulations
relative
approved
products
well
risks
related
potential
pathways
positions
may
future
advanced
fda
overcome
seven
year
orphan
drug
exclusivity
granted
fda
approved
nasal
spray
product
competitor
assurance
successful
risk
competitor
obtains
fda
orphan
drug
exclusivity
product
active
moiety
drug
products
seeking
fda
approval
earlier
approved
competitor
orphan
drug
blocks
product
candidates
seven
years
indication
risk
inherent
commercializing
new
product
including
technology
risks
financial
risks
market
risks
implementation
risks
regulatory
limitations
risks
uncertainties
concerning
potential
monetization
royalty
revenue
stream
kynmobi
apomorphine
sufficiency
net
proceeds
monetization
satisfaction
compliance
senior
notes
obligations
applicable
risk
development
sales
marketing
capabilities
risk
legal
costs
associated
outcome
patent
litigation
challenging
third
party
risk
generic
sale
proprietary
products
risk
sufficient
capital
cash
resources
including
access
available
debt
equity
financing
revenues
operations
satisfy
longer
term
cash
requirements
cash
needs
times
amounts
needed
risk
failure
satisfy
financial
debt
covenants
default
risk
related
government
claims
indivior
license
manufacture
sell
accounts
substantial
part
current
operating
revenues
risk
associated
indivior
cessation
production
authorized
generic
buprenorphine
naloxone
film
product
including
impact
loss
orders
authorized
generic
product
risk
eroding
market
share
suboxone
risk
sunsetting
product
risks
related
outsourcing
certain
sales
marketing
operational
staff
functions
third
parties
risk
rate
degree
market
acceptance
product
product
candidates
success
competing
products
including
generics
risk
size
growth
product
markets
risks
compliance
fda
governmental
customer
requirements
manufacturing
facilities
risks
associated
intellectual
property
rights
infringement
claims
relating
company
products
risk
unexpected
patent
developments
impact
existing
future
legislation
regulatory
provisions
product
exclusivity
legislation
regulatory
actions
affecting
pharmaceutical
product
pricing
reimbursement
access
claims
risks
may
arise
regarding
safety
efficacy
company
products
product
candidates
risk
loss
significant
customers
risks
related
legal
proceedings
including
patent
infringement
investigative
antitrust
litigation
matters
changes
government
laws
regulations
risk
product
recalls
withdrawals
uncertainties
related
general
economic
political
business
industry
regulatory
market
conditions
unusual
items
uncertainties
affecting
company
described
risk
factors
section
sections
included
annual
report
form
quarterly
reports
form
current
reports
form
filed
securities
exchange
commission
sec
given
uncertainties
place
undue
reliance
statements
speak
date
made
subsequent
statements
attributable
us
person
acting
behalf
expressly
qualified
entirety
cautionary
statement
company
assumes
obligation
update
statements
outlook
guidance
date
press
release
whether
result
new
information
future
events
otherwise
except
may
required
applicable
law
aquestive
logo
registered
trademarks
aquestive
therapeutics
registered
trademarks
referenced
herein
property
respective
owners
investor
inquiries
stephanie
carrington
